Phase 2 Alzheimer's Disease Trial, Recruiting NCT07236190 Sponsor: Massachusetts General Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07236190
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 55 years of age or older (men and women)
  • You have been diagnosed with subjective cognitive impairment, mild cognitive impairment (MCI), or Alzheimer's disease dementia based on recognized medical guidelines
  • Your dementia and memory test scores fall within a certain range, showing mild-to-moderate (but not severe) impairment (confirm with trial site)
  • A blood or brain scan test shows signs of Alzheimer's-related changes in your brain (confirm with trial site)
  • Your score on a depression screening questionnaire suggests you do not have significant depression
  • Any medications you take for memory or cognition have been at a stable dose for at least 3 months
  • You have good enough vision and hearing to complete all study tests
  • You have a friend, family member, or caregiver who spends meaningful time with you (at least 1 hour per day or 1 full day per week) and can help support your participation
  • Your general health is stable enough to allow you to participate in the study

Who may not be able to join:

  • Your memory or cognitive test scores indicate severe impairment
  • You have had a significant brain condition in the last 2 years, such as a brain tumor, seizures, a blood clot on the brain, or a stroke affecting the brain's outer layer
  • You have had problems with alcohol or drug misuse in the last 2 years
  • You have had major depression, severe anxiety, schizophrenia, bipolar disorder, or another major psychiatric condition in the last year
  • Your blood tests show a treatable cause for your memory problems, such as a vitamin B12 deficiency, thyroid problem, or active urinary tract infection
  • You have unstable or serious heart disease, such as frequent chest pain or severe heart failure
  • You have uncontrolled high blood pressure (above 160/100)
  • You have symptoms of a significant drop in blood pressure when you stand up
  • You have diabetes that requires insulin injections
  • You have been diagnosed with cancer in the last 5 years (with some exceptions for certain low-risk prostate or skin cancers — confirm with trial site)
  • You need to visit a doctor more than once a month for an ongoing illness
  • You are currently taking certain medications, including Alzheimer's disease monoclonal antibody treatments (such as aducanumab or lecanemab), certain supplements, unstabilized brain or psychiatric medications, steroids, strong painkillers, or antipsychotic medications (confirm specific medications with trial site)
  • You are currently taking part in another Alzheimer's disease treatment trial
  • You are currently pregnant, or become pregnant during the trial
  • You are a woman who could become pregnant and do not meet specific criteria (such as being post-menopausal for at least 12 months or having had a hysterectomy) — additional pregnancy testing during the trial would be required (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gene Bowman, ND, MPH, Harvard/Massachusetts General Hospital

Phone: 857-282-5197

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

plasma p-tau217; plasma glial fibrillary acidic protein; plasma neurofilament light chain; plasma abeta42 / abeta40; Safety and Tolerability of NPC1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov